Clinical trials: CNV
Macular Degeneration
Pegaptanib Sodium on Foveal Thickening in Patients With Exudative Subfoveal Age-Related Macular Degeneration (AMD)
The purpose of this study is to determine if Macugen™ reduces foveal thickness and improves vision in patients with wet AMD.
- Trial name
- NCT00087763
- Testing
- Macugen ™ (pegaptanib sodium injection)
- Volunteers
- 135 people
- Sponsor
- Eyetech Pharmaceuticals
Macular Degeneration
Clinical Study Of Pegaptanib Sodium (EYE001) For Wet-Type Age-Related Macular Degeneration
This study will examine the safety and efficacy of pegaptanib sodium in Japanese patients with wet-type age-related macular degeneration (AMD), who benefit further treatment and who want to continue the treatment after completion…
- Trial name
- NCT00239928
- Testing
- pegaptanib sodium
- Where
- 12 sites in Japan
- Volunteers
- 61 people
- Sponsor
- Pfizer
Macular Degeneration
An Extension to Study MD7108240
This is a two month study to allow continued treatment with pazopanib eye drops. Study may be extended to 5 months.
- Trial name
- NCT00733304
- Testing
- Pazopanib
- Where
- 17 sites in United States, Australia and 1 more
- Volunteers
- 42 people
- Sponsor
- GlaxoSmithKline
Wet Age-related Macular Degeneration, Age-related Macular Degeneration
Study to Evaluate the Safety and Effectiveness of IRay in Wet Age-related Macular Degeneration (AMD) Patients With Recurrent Leakage Secondary to Choroidal Neovascularisation (CNV)
The objective of this study is to confirm the safety and to establish the effectiveness of low voltage external beam radiosurgery using the IRay System for the treatment of subjects with recurrent leakage secondary to neovascular…
- Conditions
- Wet Age-related Macular Degeneration, Age-related Macular Degeneration, AMD, Wet AMD
- Trial name
- NCT01339949
- Testing
- IRay
- Where
- 3 sites in Italy, United Kingdom
- Sponsor
- Oraya Therapeutics, Inc.
Macular Degeneration
To Evaluate the Pharmacodynamics, Safety, and Pharmacokinetics of Pazopanib Drops in Adult Subjects With Neovascular AMD
This is a 28 day study to evaluate the pharmacodynamic effect of pazopanib eye drops on the central retinal thickness of AMD patients
- Trial name
- NCT00612456
- Testing
- Pazopanib
- Where
- 27 sites in United States, Australia and 2 more
- Volunteers
- 70 people
- Sponsor
- GlaxoSmithKline
Wet Age-Related Macular Degeneration
Safety and Tolerability of an Intravenous Infusion of ACZ885 in Patients With Wet Age-Related Macular Degeneration
This study evaluates the tolerability and safety of a single intravenous infusion of ACZ885. It also explores the efficacy of the compound in central macular edema and visual acuity in patients with wet age-related macular edema.
- Trial name
- NCT00503022
- Testing
- ACZ885
- Where
- 8 sites in Switzerland, United Kingdom
- Volunteers
- 20 people
- Sponsor
- Novartis
Neovascular (Wet) Age-related Macular Degeneration
A Study to Learn How Well Aflibercept Injected Into the Eye Works and How Safe it is When Given in Customized Treatment Intervals in Patients With an Eye Disease Called Neovascular Age-related Macular Degeneration After Start of Treatment
Researchers are looking for a better way to treat people who have neovascular (wet) age-related macular degeneration (nAMD or wet AMD).
- Trial name
- XPAND (NCT05473715)
- Testing
- Aflibercept(BAY86-5321, Eylea)
- Where
- 3 sites in Canada, United Kingdom
- Volunteers
- 3 people
- Sponsor
- Bayer
Neovascular Age-related Macular Degeneration
Evaluation the Pharmacokinetics, Safety, Tolerability of TK001 in Patients With Neovascular Age-related Macular Degeneration
The purpose of this first-in-human study is to evaluate the safety, pharmacokinetics and tolerability of single ascending doses of TK001(Recombinant humanized anti-VEGF monoclonal antibody) to determine the maximum tolerated dose…
- Trial name
- NCT02613559
- Testing
- TK001
- Where
- China
- Volunteers
- 27 people
- Sponsor
- Jiangsu T-Mab Biopharma Co.,Ltd
Age Related Macular Degeneration
Usability of the Foresee Home in Intermediate Age Related Macular Degeneration (AMD) Patients
The study purpose is to demonstrate that the target population can receive a packed FORESEE HOME unpack it, install and operate it to an extent that the FORESEE HOME can monitor them for changes in the visual field with good…
- Trial name
- UU2 (NCT00748384)
- Where
- 2 sites in Israel
- Volunteers
- 30 people
- Sponsor
- Notal Vision Ltd.
Choroidal Neovascularization, Age-Related Maculopathy
Safety and Efficacy of a New Treatment as Adjunctive Therapy to Anti-vascular Endothelial Growth Factor (Anti-VEGF) Treatment in Patients With Age-Related Macular Degeneration (AMD)
The study will evaluate the safety and efficacy of the intravitreal implant of dexamethasone with Anti-VEGF treatment vs. Anti-VEGF alone (with sham dexamethasone injection) in patients with subfoveal choroidal neovascularization…
- Trial name
- NCT00511706
- Testing
- dexamethasone, ranibizumab
- Where
- 9 sites in United States, Australia and 7 more
- Volunteers
- 243 people
- Sponsor
- Allergan
Age Related Macular Degeneration
Phase II Open Label Multicenter Study For Age Related Macular Degeneration Comparing PF-04523655 Versus Lucentis In The Treatment Of Subjects With CNV (MONET Study).
The aim of the study is to evaluate whether PF-04523655 is effective in the treatment of neovascular/wet AMD and at which dose.
- Trial name
- MONET (NCT00713518)
- Testing
- 0.5 mg ranibizumab, 3 mg PF-04523655, 1 mg PF-04523655
- Where
- 31 sites in United States, Austria and 9 more
- Volunteers
- 152 people
- Sponsor
- Quark Pharmaceuticals
Idiopathic Polypoidal Choroidal Vasculopathy
A Study to Establish the Safety and Tolerability of Zimura™ (Anti-C5 Aptamer) in Combination With Anti-VEGF Therapy in Subjects With Idiopathic Polypoidal Choroidal Vasculopathy (IPCV)
The objectives of this study are to evaluate the safety and tolerability of Zimura™ intravitreous injection in combination with anti-vascular endothelial growth factor (VEGF) therapy in subjects with Idiopathic Polypoidal…
- Trial name
- NCT02397954
- Testing
- Avacincaptad Pegol
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Ophthotech Corporation
Wet Age-related Macular Degeneration, Neovascular Age-related Macular Degeneration
Long-term Study of ADVM-022 in Neovascular (Wet) AMD [OPTIC-EXT]
ADVM-022-07 is an observational long-term extension (OPTIC-EXT) study assessing safety and efficacy of ADVM-022 gene therapy product, in participants with neovascular, or exudative (wet), age-related macular degeneration (nAMD).
- Trial name
- NCT04645212
- Testing
- ADVM-022
- Where
- 9 sites in United States
- Volunteers
- 23 people
- Sponsor
- Adverum Biotechnologies, Inc.
Age-Related Macular Degeneration
Photodynamic Therapy in Occult-Only Lesions (POOL)
Age related macular degeneration is the leading cause of blindness for people over 50 in the western world. Blood vessels which start to grow form a lesion in the back of the eye.
- Trial name
- NCT00135837
- Testing
- Verteporfin for injection
- Where
- Switzerland
- Volunteers
- 202 people
- Sponsor
- Novartis
Diabetic Macular Edema, Diabetic Retinopathy
Long-Term Follow-up Study of ADVM-022 in DME (INFINITY-EXT)
This is a prospective, observational study designed to evaluate the long-term safety and tolerability of ADVM-022 in participants with diabetic macular edema (DME).
- Trial name
- NCT05607810
- Testing
- ADVM-022
- Where
- 7 sites in United States, Puerto Rico
- Volunteers
- 22 people
- Sponsor
- Adverum Biotechnologies, Inc.
Subfoveal Choroidal Neovascularization(CNV) Secondary to Age-related Macular Degeneration (AMD)
Safety and Efficacy of Ranibizumab in Japanese Patients With Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration
Open-label Multicenter, Phase I/II Study comprising three phases (single dose, multiple dose and extension phase), Assessing the Safety and Efficacy of Ranibizumab (RFB002) in Japanese Patients With Subfoveal Choroidal…
- Trial name
- NCT00284089
- Testing
- Ranibizumab
- Where
- Japan
- Volunteers
- 88 people
- Sponsor
- Novartis
Macular Degeneration
Use of Immune Globulin Intravenous (Human) To Treat Age-Related Macular Degeneration
This study will evaluate visual improvement in patients treated with Immune Globulin Intravenous (Human), 10% Caprylate/Chromatography Purified (IGIV-C) or placebo who have Age-Related Macular Degeneration (AMD) with occult…
- Trial name
- NCT00220805
- Testing
- Immune Globulin Intravenous [Human], 10% Caprylate/Chromatography Purified, Albumin (Human) 25%, United States Pharmacopeia (USP)
- Where
- 7 sites in Germany
- Volunteers
- 96 people
- Sponsor
- Grifols Therapeutics LLC
Age-Related Macular Degeneration
A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Lucentis® Compared to Lucentis® Monotherapy
The objectives of this study are to evaluate the safety and efficacy of intravitreal administration of Fovista® administered in combination with Lucentis® compared to Lucentis® monotherapy in subjects with subfoveal choroidal…
- Trial name
- NCT01944839
- Testing
- E10030, ranibizumab
- Where
- 115 sites in United States, Austria and 11 more
- Volunteers
- 619 people
- Sponsor
- Ophthotech Corporation
Macular Degeneration, Choroidal Neovascularization
Episcleral Brachytherapy for the Treatment of Wet AMD
This is a prospective, multi-site, safety and feasibility study of the SalutarisMD SMD-DA system for retrobulbar minimally invasive episcleral brachytherapy device in patients receiving and not responding to anti-VEGF therapy for…
- Trial name
- NEAMES (NCT02988895)
- Testing
- episcleral brachytherapy
- Where
- 2 sites in United States
- Volunteers
- 11 people
- Sponsor
- Salutaris Medical Devices, Inc.
Age-Related Macular Degeneration
A 24 Month Phase 2a Open Label, Randomized Study of Avastin®, Lucentis®, or Eylea® (Anti-VEGF Therapy) Administered in Combination With Fovista® (Anti-PDGF BB Pegylated Aptamer)
To evaluate the safety of intravitreal (IVT) Fovista® administered in combination with anti-VEGF therapy.
- Trial name
- NCT02387957
- Testing
- Fovista®, bevacizumab, ranibizumab
- Where
- 24 sites in United States
- Volunteers
- 63 people
- Sponsor
- Ophthotech Corporation